scholarly journals Understanding the lung cancer mortality reductions produced by low-dose CT screening—Authors’ reply

2022 ◽  
Vol 12 ◽  
pp. 100259
Author(s):  
Stephen W. Duffy ◽  
John K. Field
Keyword(s):  
Lung Cancer ◽  
Cancer Mortality ◽  
Low Dose ◽  
Lung Cancer Mortality ◽  
Ct Screening ◽  
Low Dose Ct

scholarly journals Low-dose CT screening can reduce cancer mortality: A meta-analysis

2019 ◽  
Vol 65 (12) ◽  
pp. 1508-1514 ◽  
Author(s):  
Xue Tang ◽  
Guangbo Qu ◽  
Lingling Wang ◽  
Wei Wu ◽  
Yehuan Sun
Keyword(s):  
Lung Cancer ◽  
Cancer Mortality ◽  
Low Dose ◽  
Screening Program ◽  
Meta Analysis ◽  
Lung Cancer Mortality ◽  
Cochrane Library ◽  
Lung Cancers ◽  
Ct Screening ◽  
Low Dose Ct

SUMMARY OBJECTIVE Lung cancer is the leading cause of cancer-related death. To reduce lung cancer mortality and detect lung cancer in early stages, low dose CT screening is required. A meta-analysis was conducted to verify whether screening could reduce lung cancer mortality and to determine the optimal screening program. METHODS We searched PubMed, Web of Science, Cochrane library, ScienceDirect, and relevant Chinese databases. Randomized controlled trial studies with participants that were smokers older than 49 years (smoking >15 years or quit smoking 10 or 15 years ago) were included. RESULTS Nine RCT studies met the criteria. LDCT screening could find more lung cancer cases (RR=1.58, 95%CI=1.25-1.99, P<0.001) and more stage I lung cancers (RR=3.45, 95%CI=2.08-5.72, P<0.001) compared to chest-X ray or the no screening group. This indicated a statistically significant reduction in lung-cancer-specific mortality (RR=0.84, 95%CI=0.75-0.95, P=0.004), but without a statistically reduction in mortality due to all causes (RR=1.26, 95%CI=0.89-1.78, P=0.193). Annually, LDCT screening was sensitive in finding more lung cancers. CONCLUSIONS Low-dose CT screening is effective in finding more lung cancer cases and decreasing the deaths from lung cancer. Annual low-dose CT screening may be better than a biennial screening to detect more early-stage lung cancer cases.

scholarly journals Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study

2013 ◽  
Vol 107 (5) ◽  
pp. 702-707 ◽  
Author(s):  
Juan P. de-Torres ◽  
Ciro Casanova ◽  
Jose M. Marín ◽  
Jorge Zagaceta ◽  
Ana B. Alcaide ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pilot Study ◽  
Cancer Mortality ◽  
Low Dose ◽  
Lung Cancer Mortality ◽  
Low Dose Ct ◽  
Copd Patients ◽  
The Impact

A decrease in lung cancer mortality following the introduction of low-dose chest CT screening in Hitachi, Japan

Lung Cancer ◽  
2012 ◽  
Vol 78 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Takeshi Nawa ◽  
Tohru Nakagawa ◽  
Tetsuya Mizoue ◽  
Suzushi Kusano ◽  
Tatsuya Chonan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Mortality ◽  
Low Dose ◽  
Lung Cancer Mortality ◽  
Chest Ct ◽  
Ct Screening

Low-Dose CT Screening for Lung Cancer

2016 ◽  
Author(s):  
Christoph I. Lee
Keyword(s):  
Lung Cancer ◽  
Low Dose ◽  
Lung Cancer Mortality ◽  
Clinical Implications ◽  
Clinical Context ◽  
Ct Screening ◽  
Low Dose Ct ◽  
Additional Information ◽  
Study Methodology ◽  
Low Dose Computed Tomography

This chapter, found in the cancer screening and management section of the book, provides a succinct synopsis of a key study examining the efficacy of low-dose computed tomography screening for lung cancer. This summary outlines the study methodology and design, major results, limitations and criticisms, related studies and additional information, and clinical implications. The study showed that annual low-dose CT screening among high-risk individuals decreases lung cancer mortality. While the rate of false positives was nearly 3 times higher for those screened by low-dose CT compared to chest radiography, complications from invasive diagnostic evaluation after positive screens were rare. In addition to outlining the most salient features of the study, a clinical vignette and imaging example are included in order to provide relevant clinical context.

scholarly journals Estimate of Lung Cancer Mortality From Low-Dose Spiral Computed Tomography Screening Trials: Implications for Current Mass Screening Recommendations

2004 ◽  
Vol 22 (11) ◽  
pp. 2202-2206 ◽  
Author(s):  
Edward F. Patz ◽  
Stephen J. Swensen ◽  
James E. Herndon
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
High Risk ◽  
Mass Screening ◽  
Cancer Mortality ◽  
Low Dose ◽  
Lung Cancer Mortality ◽  
High Risk Population ◽  
Ct Screening ◽  
Screening Trials

Purpose Low-dose computed tomography (CT) has been suggested for lung cancer screening. Several observational trials have published their preliminary results, and some investigators suggest that this technique will save lives. There are no mortality statistics, however, and the current study used published data from these trials to estimate the disease-specific mortality in this high-risk population. Patients and Methods Two nonrandomized CT screening trials were selected from the literature for analysis. The number of trial participants, the number of lung cancers diagnosed per year, and stage distribution of the cancers was recorded. Previously published 5-year survival data were used to calculate the number of predicted lung cancer deaths and estimate the overall lung cancer mortality per 1,000 person-years among participants screened. These statistics were then compared to the previous Mayo Lung Project, which used chest radiographs and sputum cytology for screening high-risk individuals. Results This study estimates the lung cancer mortality is 4.1 deaths per 1,000 person-years in the Mayo Clinic CT screening trial, and is 5.5 deaths per 1,000 person-years in the Early Lung Cancer Action Program trial. These data are similar to the lung cancer mortality of 4.4 deaths per 1,000 person-years in the interventional arm, and 3.9 deaths per 1,000 person-years in the usual-care arm of the previous Mayo Lung Project. Conclusion These data suggest that CT screening could produce similar outcomes to prior chest radiographic trials in this high-risk group. Results from randomized trials are required, however, before the true utility of mass screening with CT for lung cancer can be determined.

Sign in / Sign up

Export Citation Format

Share Document